doi:10.1002/jgh3.12785

EDITORIAL

Hypnotherapy and IBS: Time to take control of the Asian gut

The 2014 revised definition from the American Psychological Association's Division 30 describes hypnosis as "a state of consciousness involving focused attention and reduced peripheral awareness characterized by an enhanced capacity for response to suggestion." Hypnotherapy refers to the use of hypnosis in the treatment of a medical or psychological disorder or concern. The treatment involves a one-to-one 30–60 min session with a trained therapist, at weekly intervals, for 6–12 weeks.

Gut-directed hypnotherapy (GDH) uses suggestions or metaphors to imply control and normalization of gastrointestinal function. The patient is first educated regarding basic anatomy and physiology, and how disturbance of this normal function can produce symptoms. They are then taught various skills to enable them to gain control of their gut function, often using metaphors or tactile approaches. GDH has proven benefits to patients in terms of symptom improvement and decreased medical expenditure. It is recognized as an effective psychological treatment for IBS in recent clinical guidelines.² Yet despite being an effective treatment for IBS, hypnotherapy remains under-prescribed. Why is this so?

One reason could be due to misconceptions that patients have regarding hypnotherapy. Patients commonly hold the misbelief that hypnotherapists can make them act against their will or even expose their personal secrets. In truth, hypnotherapy is used as a powerful means of teaching patients how to control their minds and bodies. Studies have shown that patients with higher hypnotic susceptibility benefit from improvement in symptom severity, health-related quality of life, and coping patterns after hypnotherapy treatment. Some research has shown that skepticism and apprehension were often common before treatment and transformed to enthusiasm afterward.³

There is an additional uncertainty about the mechanism of action of hypnotherapy. It is suggested that GDH works on the brain–gut axis to improve GI symptoms in IBS patients. In patients who had undergone hypnosis therapy, brain response to distension was similar to that observed in healthy controls, suggesting that the treatment had a normalizing effect on the central processing abnormality of visceral signals in IBS.⁴ Past studies on intestinal microbiota composition and GI motility before and after hypnotherapy did not find any difference.⁵

Lack of familiarity is yet another barrier to hypnotherapy. The first hypnotherapy trial for IBS was published by Whorwell et al. in 1984. They compared the effect of psychotherapy and hypnotherapy for 30 severe refractory IBS patients. Whorwell et al. reported that hypnotherapy treatment was superior to psychotherapy but should be reserved for refractory cases as it is time-consuming. Since then more studies have been performed to investigate the effect of hypnotherapy on IBS. A recent metanalysis of the effect of hypnotherapy on the treatment of IBS suggested that the data are promising and the treatment is likely

to be beneficial, but concluded that more study is needed before a conclusion can be made.⁷ Furthermore, despite early suggestions that hypnotherapy should be reserved for refractory IBS patients and only performed in tertiary centers, we now know that group hypnotherapy and hypnotherapy through telemedicine or even a mobile phone application work equally well.⁸ Furthermore, the effects of GDH have been shown to last as long as the low FODMAP diet.

Lastly, cultural differences between populations may impede the uptake of hypnotherapy in IBS. Most of the evidence for hypnotherapy in IBS has been derived from studies in Caucasian patients, with a resultant lack of recommendation for this therapy among Asian patients. In this issue of JGH OPEN, Sasegbon et al. have reported the efficacy of hypnotherapy in British refractory IBS patients of Asian descent for the first time. 9 Forty-four British Asian (predominantly Pakistani and Indian heritage) IBS patients received hypnotherapy over 12 weeks, with significant improvement in IBS symptoms (84%) achieved >50-point reduction in IBS-SSS) and quality of life. Although this study was conducted in routine clinical practice without a control group, the results were similar to controlled trials using the same outcome measures. Interestingly, the authors did not identify any difference in response between firstgeneration British Asians and those born in the United Kingdom, nor whether the therapist was of Asian descent or not. While the current study indicates that refractory IBS patients of Asian descent are likely to benefit from hypnotherapy, it is uncertain if the same is true for IBS patients residing in Asia. It is recognized that while some cultural practices and health beliefs are retained when Asians migrate to the West, many are known to change and adopt the practices of their host countries. 10

Hypnotherapy has a definite role to play in refractory IBS. Misconceptions and lack of awareness will need to be overcome by education and promotion. The current study by Sasegbon et al. suggests that cultural factors and health beliefs among Asian IBS patients may not be a barrier, but further studies in an Asian setting need to be conducted. However, implementing non-pharmacological therapy for IBS patients in Asia still remains a challenge. In a recent Editorial review, Chuah et al. had highlighted that many Asian countries still utilized pure pharmacological therapy in the management of IBS and lacked resources for allied healthcare services. 11 Furthermore, as such therapies are usually time-intensive and require multiple visits to an institution for treatment, acceptance by patients is thought to be poor. 12 Nevertheless, it is certainly time for Asian clinicians to acknowledge the futility of a pure pharmacological-based approach. Asian IBS patients need to be educated accordingly and need to start "taking-control" of their symptoms!

Hypnotherapy and IBS KTH Siah and S Mahadeva

Kewin Tien Ho Siah*, and Sanjiv Mahadeva Division of Gastroenterology & Hepatology, University Medicine Cluster, National University Hospital, Department of Internal Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore and Division of Gastroenterology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Correspondence

Sanjiv Mahadeva, Division of Gastroenterology, Department of Medicine Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Email: sanjiv@ummc.edu.my

References

- 1 Elkins GR, Barabasz AF, Council JR, Spiegel D. Advancing research and practice: the revised APA division 30 definition of hypnosis. *Am. J. Clin. Hypn.* 2015; 57: 378–85.
- 2 Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable Bowel Syndrome. Gut. 2021; 70: 1214–40.
- 3 Wan YP, Ng SM. Hypnotherapy for persons with Irritable Bowel Syndrome: A three-arm randomized controlled trial. Am. J. Clin. Hypn. 2022; 12: 1–26.

- 4 Lowén MB, Mayer EA, Sjöberg M *et al.* Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable Bowel Syndrome. *Aliment. Pharmacol. Ther.* 2013 Jun; **37**: 1184–97
- 5 Peter J, Fournier C, Keip B et al. Intestinal microbiome in irritable Bowel Syndrome before and after gut-directed hypnotherapy. Int. J. Mol. Sci. 2018; 19(11): 3619.
- 6 Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-Bowel Syndrome. *Lancet.* 1984; 2: 1232–4.
- 7 Lee HH, Choi YY, Choi MG. The efficacy of hypnotherapy in the treatment of irritable Bowel Syndrome: A systematic review and meta-analysis. J. Neurogastroenterol. Motil. 2014; 20: 152–62.
- 8 Hasan SS, Pearson JS, Morris J, Whorwell PJ. Skype hypnotherapy for irritable Bowel Syndrome: Effectiveness and comparison with face-to-face treatment. *Int. J. Clin. Exp. Hypn.* 2019; 67: 69–80.
- 9 Sasegbon A, Hasan SS, Whorwell PJ, Vasant DH. Experience and clinical efficacy of gut-directed hypnotherapy in an Asian population with refractory irritable Bowel Syndrome. *JGH Open* 2022; 6: 447–53.
- 10 Xie Z, St Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS One. 2019; 14: e0212117.
- 11 Chuah KH, Mahadeva S. The challenges of implementing evidence based therapy for irritable Bowel Syndrome in Asia. *JGH Open*. 2021; 5: 1225–6.
- 12 Mahadeva S. Non-pharmacological intervention in functional dyspepsia: Is this the way forward? *J. Gastroenterol. Hepatol.* 2021; 36: 2031–2.